EGFR and small cell lung carcinoma: In the off-target group, bypass signaling activation (such as the other RTKs: EGFR, KIT, IGF1R and downstream signaling molecules; SRC, MEK/ERK) [178,179,180] and morphological alterations (small cell lung cancer and epithelial-mesenchymal transition) contribute to this resistance [181,182,183].